专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012113834A1 METHOD AND USE OF METABOLITES FOR THE DIAGNOSIS OF INFLAMMATORY BRAIN INJURY IN PRETERM BORN INFANTS 审中-公开
标题翻译：代谢物对前列腺免疫缺陷性脑损伤诊断的方法与用途
公开(公告)号：WO2012113834A1
公开(公告)日：2012-08-30
申请号：PCT/EP2012/053016
申请日：2012-02-22
申请人： BIOCRATES LIFE SCIENCES AG , KELLER, Matthias , MALLARD, Carina , DEIGNER, Hans-Peter , ENOT, David , IGWE, Emeka I.
发明人： KELLER, Matthias , MALLARD, Carina , DEIGNER, Hans-Peter , ENOT, David , IGWE, Emeka I.
IPC分类号： G01N33/68
CPC分类号： G06F19/10 , G01N33/483 , G01N33/6896 , G01N2800/38
摘要： The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.
摘要翻译：本发明涉及使用选自酰基肉毒碱，二酰基磷脂酰胆碱，酰基 - 烷基磷脂酰胆碱，溶血磷脂酰胆碱和氨基酸的多种内源性目标代谢物来预测早产婴儿发炎相关脑损伤的可能性的新型生物标志物。

2. 发明申请

WO2011012553A1 METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE 审中-公开
标题翻译：预测感染相关器官失败发生率的方法
公开(公告)号：WO2011012553A1
公开(公告)日：2011-02-03
申请号：PCT/EP2010/060745
申请日：2010-07-23
申请人： BIOCRATES LIFE SCIENCES AG , DEIGNER, Hans-Peter , KOHL, Matthias , ENOT, David , KOAL, Therese , KELLER, Matthias
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , ENOT, David , KOAL, Therese , KELLER, Matthias
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/26 , G06F19/12 , G06F19/24 , Y10T436/173845
摘要： The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method.
摘要翻译：本发明涉及用于通过受试者的定量代谢组学谱来预测来自哺乳动物受试者的体外生物样品的炎症相关器官功能衰竭发作的可能性的可靠和统计学显着的方法，该定量代谢组学特征包括多种内源性代谢物，并将其与多种内源性器官衰竭预测目标代谢物的定量参考代谢组学谱进行比较，以便预测受试者是否可能或不可能发生器官功能衰竭。此外，本发明涉及在这种方法中内源性器官衰竭预测目标代谢物的有用性。

3. 发明申请

WO2010128054A1 METHOD OF DIAGNOSING ASPHYXIA 审中-公开
标题翻译：诊断ASPHYXIA的方法
公开(公告)号：WO2010128054A1
公开(公告)日：2010-11-11
申请号：PCT/EP2010/056048
申请日：2010-05-04
申请人： BIOCRATES LIFE SCIENCES AG , KELLER, Matthias , DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , SOLBERG, Ronnaug , SAUGSTAD, Ola Didrik , KOAL, Therese
发明人： KELLER, Matthias , DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , SOLBERG, Ronnaug , SAUGSTAD, Ola Didrik , KOAL, Therese
IPC分类号： G01N33/68 , G06F19/00
CPC分类号： G01N33/6893 , G01N2800/12 , G06F19/24 , Y02A90/26
摘要： The present invention relates to a method for in vitro diagnosing asphyxia and disorders related thereto, to a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and to a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, characterized by quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.
摘要翻译：本发明涉及一种用于体外诊断窒息和相关疾病的方法，体外估计患有窒息的患者的缺氧持续时间的方法，以及用于体外监测正常氧，缺氧和高氧条件的方法，以及 /或常压和高压氧疗法，其特征在于在患者的生物样品中定量检测多种选自生物胺的窒息特异性内源性化合物; 肉碱衍生化合物; 氨基酸; 胆汁酸羧酸; 花生酸类; 脂质; 胆固醇前体，胆固醇代谢物; 前列腺素; 和糖。

4. 发明申请

WO2011157655A1 USE OF BILE ACIDS FOR PREDICTION OF AN ONSET OF SEPSIS 审中-公开
标题翻译：使用双酸来预测食欲的上升
公开(公告)号：WO2011157655A1
公开(公告)日：2011-12-22
申请号：PCT/EP2011/059699
申请日：2011-06-10
申请人： BIOCRATES LIFE SCIENCES AG , DEIGNER, Hans-Peter , KOHL, Matthias , KOAL, Therese , IGWE, Ignatius Emeka , DALLMANN, Guido , BAUER, Michael , ENOT, David
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , KOAL, Therese , IGWE, Ignatius Emeka , DALLMANN, Guido , BAUER, Michael , ENOT, David
IPC分类号： G01N33/50 , G01N33/92
CPC分类号： G01N33/6893 , G01N30/7233 , G01N33/6848 , G01N33/92 , G01N2030/8813 , G01N2800/24 , G01N2800/26 , G01N2800/50
摘要： The present invention relates to a method for in vitro predicting the likelihood of an onset of sepsis, by quantitatively detecting in at least one biological sample of a patient a plurality of endogenous sepsis predictive target compounds having a molecular weight of less than 1500 Dalton comprising the steps of: selecting said compounds from the group of bile acids, measuring concentration, level or amount of each individual endogenous sepsis predictive target compound of said plurality of compounds in said sample, establishing a quantitative pattern; and using and storing the obtained set of values in a database. Calibrating said values by comparing clinically confirmed sepsis-positive and/or clinically confirmed sepsis-negative reference parameters, and comparing said measured values in the sample with the calibrated values, in order to assess whether the patient is likely to develop a sepsis or not.
摘要翻译：本发明涉及通过在患者的至少一个生物样品中定量检测多个分子量小于1500道尔顿的内源性败血症预测靶化合物来体外预测败血症发作的可能性的方法，所述内源性败血症预测靶化合物包含步骤：从所述胆汁酸组中选择所述化合物，测量所述样品中所述多种化合物的每种单独内源性败血症预测目标化合物的浓度，水平或量，建立定量模式; 并将获得的值集合使用并存储在数据库中。通过比较临床证实的败血症阳性和/或临床证实的败血症阴性参考参数，并将样本中的所述测量值与校准值进行比较来校准所述值，以评估患者是否可能发展为败血症。

5. 发明申请

WO2011080184A1 USE OF ENDOGENOUS METABOLITES FOR EARLY DIAGNOSING SEPSIS 审中-公开
标题翻译：使用内源性代谢物进行早期诊断SEPSIS
公开(公告)号：WO2011080184A1
公开(公告)日：2011-07-07
申请号：PCT/EP2010/070544
申请日：2010-12-22
申请人： BIOCRATES LIFE SCIENCES AG , DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , IGWE, Emeka , KOAL, Therese , BAUER, Michael , DALLMANN, Guido
发明人： DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , IGWE, Emeka , KOAL, Therese , BAUER, Michael , DALLMANN, Guido
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2800/26
摘要： The present invention relates to a use of a plurality of endogenous target metabolites for predicting a likelihood of an onset of a sepsis from a biological sample of a mammalian subject in vitro, wherein said endogenous target metabolites have a molecular mass less than 1500 Da and are selected from the group of oxysterols.
摘要翻译：本发明涉及多种内源性目标代谢物用于从体外预测来自哺乳动物受试者的生物样品的脓毒症发作的可能性的用途，其中所述内源靶标代谢物具有小于1500Da的分子量，并且分别为选自氧固醇组。

6. 发明申请

WO2011092286A1 DIAGNOSING PROSTATE CANCER RELAPSE 审中-公开
标题翻译：诊断前列腺癌相关
公开(公告)号：WO2011092286A1
公开(公告)日：2011-08-04
申请号：PCT/EP2011/051209
申请日：2011-01-28
申请人： IMG INSTITUT FÜR MEDIZINISCHE GENOMFORSCHUNG PLANUNGSGESELLSCHAFT M.B.H. , WEINBERGER, Klaus , DEIGNER, Hans-Peter , IGWE, Emeka Ignatius , ENOT, David , DALLMANN, Guido , KLOCKER, Helmut
发明人： WEINBERGER, Klaus , DEIGNER, Hans-Peter , IGWE, Emeka Ignatius , ENOT, David , DALLMANN, Guido , KLOCKER, Helmut
IPC分类号： G01N33/574
CPC分类号： G01N33/57434 , G01N2800/54
摘要： The invention discloses the use of at least one substance selected from the group consisting of Phosphatidylcholine with diacyl residue sum C24:0 (PC aa C24:0); Phosphatidylcholine with diacyl residue sum C40:3 (PC ae C40:3); Phosphatidylcholine with diacyl residue sum C40:4 (PC ae C40:4); Lysophosphatidylcholine with acyl residue sum C26:0 (lysoPC a C26:0); Lysophosphatidylcholine with acyl residue sum C6:0 (lysoPC a C6:0); 13(S)-hydroxy-9Z,11E-octadecadienoic acid (13S-HODE); 12(S)-hydroxy- 5Z, 8Z, 10E,14Z-eicosatetraenoic acid (12S-HETE); 15(S)-hydroxy- 5Z, 8Z, 11Z, 13E-eicosatetraenoic acid (15S-HETE); Leukotriene B4 (LTB4); Prostaglandin E2 (PGE2); Prostaglandin D2 (PGD2); 7α- Hydroxycholesterol (7aOHC); 7-Ketocholesterol (7KC); 5β, 6β- Epoxycholesterol (5b,6b,EPC); 5g302,6g302-Epoxycholesterol (5a, 6a, EPC); and 4β-Hydroxycholesterol (4BOHC); for prognosticating relapse of a prostate cancer (PCa) in a sample of a body fluid or a tissue sample of a PCa patient.
摘要翻译：本发明公开了使用选自由二酰基残基和C24：0（PCaa C24：0）组成的组的至少一种物质; 具有二酰基残基总数C40：3的磷脂酰胆碱（PC ae C40：3）; 具有二酰基残基的磷脂酰胆碱总数C40：4（PC ae C40：4）; 酰基残基总数为C26：0的溶血磷脂酰胆碱（lysoPC a C26：0）; 具有酰基残基的溶血磷脂酰胆碱和C6：0（溶血糖素a C6：0）; 13（S） - 羟基-9Z，11E-十八碳二烯酸（13S-HODE）; 12（S） - 羟基-5Z，8Z，10E，14Z-二十碳四烯酸（12S-HETE）; 15（S） - 羟基-5Z，8Z，11Z，13E-二十碳四烯酸（15S-HETE）; 白三烯B4（LTB4）; 前列腺素E2（PGE2）; 前列腺素D2（PGD2）; 7a-羟基胆固醇（7aOHC）; 7-酮胆固醇（7KC）; 5β，6β-环氧胆固醇（5b，6b，EPC）; 5g302,6g302-环氧胆固醇（5a，6a，EPC）; 和4β-羟基胆固醇（4BOHC）; 用于预测PCa患者体液或组织样品中前列腺癌（PCa）的复发。

7. 发明公开

EP2427773A1 METHOD OF DIAGNOSING ASPHYXIA 失效转让
标题翻译：方法的诊断窒息
公开(公告)号：EP2427773A1
公开(公告)日：2012-03-14
申请号：EP10716347.9
申请日：2010-05-04
申请人： Keller, Matthias , Enot, David
发明人： KELLER, Matthias , DEIGNER, Hans-Peter , ENOT, David , KOHL, Matthias , SOLBERG, Ronnaug , SAUGSTAD, Ola Didrik , KOAL, Therese
IPC分类号： G01N33/68 , G06F19/00
CPC分类号： G01N33/6893 , G01N2800/12 , G06F19/24 , Y02A90/26
摘要： The present invention relates to a method for in vitro diagnosing asphyxia and disorders related thereto, to a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and to a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, characterized by quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.

8. 发明公开

EP2460014A1 METHOD FOR PREDICTING THE LIKELIHOOD OF AN ONSET OF AN INFLAMMATION ASSOCIATED ORGAN FAILURE 审中-公开
标题翻译：一种用于预测点火WARHSCHEINLICHKEIT的发生Verbidnung与器官衰竭
公开(公告)号：EP2460014A1
公开(公告)日：2012-06-06
申请号：EP10737041.3
申请日：2010-07-23
申请人： BIOCRATES Life Sciences AG
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , ENOT, David , KOAL, Therese , KELLER, Matthias
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2800/26 , G06F19/12 , G06F19/24 , Y10T436/173845
摘要： The present invention relates to a reliable and statistically significant method for predicting the likelihood of an onset of an inflammation associated organ failure from a biological sample of a mammalian subject in vitro, by means of a subject's quantitative metabolomics profile comprising a plurality of endogenous metabolites, and comparing it with a quantitative reference metabolomics profile of a plurality of endogenous organ failure predictive target metabolites in order to predict whether the subject is likely or unlikely to develop an organ failure. Furthermore, the invention relates to the usefulness of endogenous organ failure predictive target metabolites in such a method.

9. 发明授权

EP2449488B1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES 有权
标题翻译：进行归一化方法在METABOLOMANALYSEVERFAHREN具有内生参比代谢物
公开(公告)号：EP2449488B1
公开(公告)日：2015-01-14
申请号：EP10726084.6
申请日：2010-06-23
申请人： BIOCRATES Life Sciences AG
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , KELLER, Matthias , KOAL, Therese , ENOT, David
IPC分类号： G06F19/24
CPC分类号： G06F19/24 , G01N2800/60 , Y10T436/163333 , Y10T436/201666

10. 发明公开

EP2449488A1 METHOD FOR NORMALIZATION IN METABOLOMICS ANALYSIS METHODS WITH ENDOGENOUS REFERENCE METABOLITES 有权
标题翻译：进行归一化方法在METABOLOMANALYSEVERFAHREN具有内生参比代谢物
公开(公告)号：EP2449488A1
公开(公告)日：2012-05-09
申请号：EP10726084.6
申请日：2010-06-23
申请人： BIOCRATES Life Sciences AG
发明人： DEIGNER, Hans-Peter , KOHL, Matthias , KELLER, Matthias , KOAL, Therese , ENOT, David
IPC分类号： G06F19/00
CPC分类号： G06F19/24 , G01N2800/60 , Y10T436/163333 , Y10T436/201666
摘要： The present invention relates to the use of endogenous reference metabolites and a method for normalization of intensity data corresponding to amounts and/or concentrations of selected target metabolites in a biological sample of a mammalian subject, wherein said intensity data are obtained by a metabolomics analysis method with one or a plurality of endogenous reference metabolites, comprising carrying out at least one in vitro metabolomics analysis method of said selected target metabolites in said biological sample, simultaneously carrying out in the same sample a quantitative analysis of one or a plurality of endogenous reference metabolites or derivatives thereof, wherein said endogenous reference metabolites are such compounds in the biological sample which are present in the subject at an essentially constant level; and wherein said endogenous reference metabolites or derivatives thereof have a molecular mass less than 1500 Da.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式